1. Home
  2. Analysis
  3. Relistor
  4. Joint-effusion

Relistor and Joint effusion - a phase IV clinical study of FDA data

Summary:

Joint effusion is reported as a side effect among people who take Relistor (methylnaltrexone bromide), especially for people who are female, 50-59 old, also take Dilaudid, and have Breast cancer.

The phase IV clinical study analyzes which people have Joint effusion when taking Relistor. It is created by eHealthMe based on reports of 1,647 people who have side effects when taking Relistor from the FDA, and is updated regularly.

What is Relistor?

Relistor has active ingredients of methylnaltrexone bromide. eHealthMe is studying from 1,659 Relistor users. Check the latest studies of Relistor.

What is Joint effusion?

Joint effusion (presence of extra fluid in joint covering) is found to be associated with 872 drugs and 750 conditions by eHealthMe. Check the latest studies of Joint effusion.

On Jul, 14, 2026

1,647 people reported to have side effects when taking Relistor.
Among them, 14 people (0.85%) have Joint effusion.

Could Relistor cause Joint effusion?

Among these 14 people:

What is the gender of people who have Joint effusion when taking Relistor? *

  • female: 100 %
  • male: 0.0 %

What is the age of people who have Joint effusion when taking Relistor? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 50 %
  • 50-59: 50 %
  • 60+: 0.0 %

What are other drugs people take besides Relistor? *

  1. Dilaudid: 14 people, 100.00%
  2. Zometa: 13 people, 92.86%
  3. Neurontin: 13 people, 92.86%
  4. Navelbine: 13 people, 92.86%
  5. Lamictal: 13 people, 92.86%
  6. Gemzar: 13 people, 92.86%
  7. Faslodex: 13 people, 92.86%
  8. Droperidol: 13 people, 92.86%
  9. Compazine: 13 people, 92.86%
  10. Percocet: 13 people, 92.86%

What are other side effects people have besides Joint effusion? *

  1. Joint Pain: 14 people, 100.00%
  2. Anaemia (lack of blood): 14 people, 100.00%
  3. Pulmonary Embolism (blockage of the main artery of the lung): 14 people, 100.00%
  4. Fatigue (feeling of tiredness): 14 people, 100.00%
  5. Pleural Effusion (water on the lungs): 14 people, 100.00%
  6. Constipation: 14 people, 100.00%
  7. White Blood Cell Count Decreased: 13 people, 92.86%
  8. Pain: 13 people, 92.86%
  9. Hypokalemia (low potassium): 13 people, 92.86%
  10. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 13 people, 92.86%

What are the existing conditions these people have? *

  1. Breast Cancer: 10 people, 71.43%
  2. Colon Cancer Metastatic (cancer of colon spreads to other part of body): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Relistor and have Joint effusion?

- Check whether Joint effusion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Relistor:

Joint effusion treatments and more:

How severe was Joint effusion and when was it recovered:

Expand to all the drugs that have ingredients of methylnaltrexone bromide:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Relistor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Joint effusion:

Browse all the conditions that are associated with Joint effusion:

How the study uses the data?

The study uses data from the FDA. It is based on methylnaltrexone bromide (the active ingredients of Relistor) and Relistor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.